InvestorsHub Logo
Followers 0
Posts 187
Boards Moderated 0
Alias Born 05/29/2013

Re: BonelessCat post# 41903

Tuesday, 09/17/2013 4:12:34 AM

Tuesday, September 17, 2013 4:12:34 AM

Post# of 403156
Let me try to answer this question more simply. From what others have posted big pharma just hasn't shown a lot of interest in the antibiotic space. Not enough repeat lifetime customers like with cholesterol and similar drugs and sexier things like cancer cures. It seems big pharma simply willingly abandoned the space, not because it doesn't have value, but because it doesn't have enough value to them to be worth pursuing - remember total antibiotic space value was something like 1.5B in U.S. so getting a piece of that pie just isn't a big deal to them. Hence no interest in a Ph2a

Could they be proven wrong in their decision making - definitely. But it does seem that it is smaller pharmas that are taking the lead in the antibiotics space and I'm sure Cubicin was distracted by their other recent acquisitions. Trius is gone cause it got eaten by the above. Realistic to ask how many interested buyers could there have even been left to compete with our bid?

Just my two cents. But I think big pharma could have moved to acquire assets in bankruptcy without too much difficulty. Its just its not exciting enough for a big company like that to bother with such a small fry (to them at least - to us its quite large potentially) indication.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News